touchONCOLOGY meets with Dr Ana Maria Arance Fernandez at ESMO 2020 to discuss findings from the LEAP-004 trial, and the role lenvatinib plus pembrolizumab can play in the treatment of advanced melanoma. The late-breaking abstract ‘Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004’ (LBA44) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.
Questions
- What is the rationale for the combined use of lenvatinib plus pembrolizumab in the treatment of advanced melanoma that has progressed on PD-1/PD-L1 inhibitor therapy? (0:11)
- Could you tell us a little about the aims and design of the LEAP-004 study? (0:38)
- What were the main efficacy and safety findings of the study? (1:33)
- What association (if any) was found between treatment response and PD-L1 status? (2:31)
- What are the remaining gaps in our knowledge and what future studies are planned? (3:01)
Speaker Disclosure: Ana Maria Arance Fernandez has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd. The LEAP-004 trial was sponspored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Filmed in coverage of the Virtual 2020 ESMO Congress.
PD-1 = Programmed cell death protein 1; PD-L1 = Programmed death-ligand 1.
